Researchers at Osaka Metropolitan University (OMU), in partnership with K.K. DNAFORM and the National Institute for Biomedical Research (INRB) in the Democratic Republic of the Congo, are developing a portable, rapid diagnostic system to detect the Bundibugyo virus (BDBV). The project, supported by the Global Health Innovative Technology Fund (GHIT Fund), aims to provide field-ready, point-of-care testing capable of producing results within 30 minutes, addressing critical diagnostic gaps during Ebola virus disease outbreaks.
Meeting the 100-Day Mission for Emerging Pathogens
The “100-Day Mission” is an international framework designed to ensure that diagnostic tools, vaccines, and therapeutics are available within 100 days of identifying a new infectious disease threat. According to OMU, the research team successfully produced a prototype test kit for BDBV in just 40 days following the World Health Organization’s declaration of a Public Health Emergency of International Concern (PHEIC).
This rapid development cycle relies on a collaborative network involving industry, academia, and government agencies. By integrating OMU’s established research infrastructure in the Democratic Republic of the Congo with K.K. DNAFORM’s portable nucleic acid testing technology, the team has created a framework intended to bypass traditional, time-consuming diagnostic bottlenecks in resource-limited settings.
Did you know? The “100-Day Mission” is an international goal aimed at ensuring diagnostic tests, treatments, vaccines, and other tools are ready to use within 100 days of the confirmation of an emerging infectious disease outbreak.
Technical Capabilities of the GenPad System
The diagnostic system, branded as “GenPad,” utilizes SmartAmp isothermal PCR technology and Eprobe detection to identify the Bundibugyo virus. Unlike traditional laboratory-based PCR, this platform is designed for portability and field use in areas lacking stable power grids.
Key technical specifications of the prototype, as reported by OMU, include:
- Weight: 460 grams, making it highly portable for field teams.
- Power: Battery-operated (7.2 VDC, 21.6 Wh), capable of running eight tests on a single charge.
- Speed: Results generated in approximately 30 minutes from blood collection.
- Sensitivity: Initial laboratory testing confirmed a limit of detection (LOD) of ≤200 copies per cartridge, meeting WHO performance criteria.
- Specificity: No cross-reactivity was observed against a panel of 86 other microbial species.
Why BDBV Requires Specialized Diagnostics
BDBV is a distinct member of the Ebolavirus genus, separate from the more commonly studied Zaire ebolavirus (EBOV). Because of these genetic differences, existing diagnostic tools and vaccines developed for EBOV cannot always be applied to BDBV. According to OMU, this necessitates the development of specific tests that can reliably detect and differentiate BDBV to ensure accurate contact tracing and patient isolation.
Field deployment presents significant logistical hurdles, including limited electricity, restricted specimen transport, and the need for specialized personnel. The GenPad system addresses these by using fully sealed cartridges, which simplify sample handling and reduce the risk of exposure for healthcare workers in high-pressure, low-resource environments.
The OMU team is currently working on a version that can differentiate BDBV, EBOV, and SUDV in a single cartridge, which would significantly streamline clinical decision-making during multi-strain outbreaks.
Future Validation and Regulatory Pathways
The research team is moving toward clinical validation in stages. Initial testing has utilized non-infectious armored RNA mimics. The next phase involves clinical performance validation in the Democratic Republic of the Congo in collaboration with the INRB.
The project is also preparing the necessary data to pursue a World Health Organization Emergency Use Listing (EUL). While the current priority remains a BDBV-specific kit, the long-term goal is to establish a versatile platform capable of responding to various future infectious disease threats. This work is supported by the Japanese government’s Global Health Strategy and the Security Technology Research Promotion Program managed by the Acquisition, Technology & Logistics Agency.
Frequently Asked Questions
What is the primary advantage of the GenPad system?
The GenPad system allows for portable, battery-powered nucleic acid testing in areas without traditional laboratory infrastructure, providing results in about 30 minutes.
Can this test detect other types of Ebola?
The current prototype is specific to the Bundibugyo virus (BDBV). However, researchers are currently developing a multiplex version that can differentiate between BDBV, EBOV, and SUDV.
Is the GenPad system currently available for clinical use?
No. According to OMU, the platform is currently under development and evaluation and is not yet intended for clinical use or commercial sale.
Are you interested in how rapid diagnostic technologies are shaping the future of global health security? Subscribe to our newsletter for the latest updates on infectious disease research and clinical innovations.
Related reading